Drug Trial Radar · NCT04855591
A Trial of SHR-1703 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Jun 14, 2021
Primary completion
Sep 13, 2021
Study completion Nov 18, 2021
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.
Conditions
- Asthma
Interventions
SHR-1703Drug
SHR-1703 will be administered subcutaneously
PlaceboDrug
Placebo of SHR-1703 will be administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Start of Treatment to end of study (approximately 34 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.